These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 17553628)
1. Erythropoietin and Parkinson's disease: Suggested mechanisms and therapeutic implications. Genc K Med Hypotheses; 2008; 70(1):211-2. PubMed ID: 17553628 [No Abstract] [Full Text] [Related]
2. Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage. Genc S; Egrilmez MY; Genc K Med Hypotheses; 2006; 67(2):424. PubMed ID: 16707229 [No Abstract] [Full Text] [Related]
3. Neuroprotection in Parkinson's disease: an elusive goal. Biglan KM; Ravina B Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255 [TBL] [Abstract][Full Text] [Related]
4. Why hasn't neuroprotection worked in Parkinson's disease? Kieburtz K; Ravina B Nat Clin Pract Neurol; 2007 May; 3(5):240-1. PubMed ID: 17479072 [No Abstract] [Full Text] [Related]
5. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106 [No Abstract] [Full Text] [Related]
6. Rasagiline -- is there a place for this drug in managing Parkinson's disease? Sharma JC Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281 [No Abstract] [Full Text] [Related]
7. New hope for mechanism-based treatment of Parkinson's disease. Bradbury J Drug Discov Today; 2005 Jan; 10(2):80-1. PubMed ID: 15718152 [TBL] [Abstract][Full Text] [Related]
8. [Initial management and adaptation of Parkinson's disease treatment]. Gérard JM Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969 [TBL] [Abstract][Full Text] [Related]
9. Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes. Lim JH; Kim SS; Boo DH; No H; Kang BY; Kim EM; Hwang O; Choi HJ Neurosci Lett; 2009 Feb; 451(3):185-9. PubMed ID: 19146917 [TBL] [Abstract][Full Text] [Related]
10. Rasagiline as a therapy for Parkinson's disease (PD). Hermanowicz N Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520 [No Abstract] [Full Text] [Related]
11. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M; Maruyama W Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610 [TBL] [Abstract][Full Text] [Related]
12. A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection. Linazasoro G Parkinsonism Relat Disord; 2009 Jul; 15(6):401-5. PubMed ID: 19346152 [TBL] [Abstract][Full Text] [Related]
13. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Clarke CE Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348 [TBL] [Abstract][Full Text] [Related]
14. An overview of novel therapies for Parkinson's disease. Fahn S Exp Neurol; 1997 Mar; 144(1):21-3. PubMed ID: 9126146 [No Abstract] [Full Text] [Related]
15. New drug treatment for Parkinson's disease. FDA Consum; 2006; 40(4):7. PubMed ID: 17245831 [No Abstract] [Full Text] [Related]